259 related articles for article (PubMed ID: 30427585)
1. Evaluation of the Short-, Mid-, and Long-Term Effects of Tofacitinib on Lymphocytes in Patients With Rheumatoid Arthritis.
van Vollenhoven R; Lee EB; Strengholt S; Mojcik C; Valdez H; Krishnaswami S; Biswas P; Lazariciu I; Hazra A; Clark JD; Hodge J; Wang L; Choy E
Arthritis Rheumatol; 2019 May; 71(5):685-695. PubMed ID: 30427585
[TBL] [Abstract][Full Text] [Related]
2. Effects of tofacitinib on lymphocytes in rheumatoid arthritis: relation to efficacy and infectious adverse events.
Sonomoto K; Yamaoka K; Kubo S; Hirata S; Fukuyo S; Maeshima K; Suzuki K; Saito K; Tanaka Y
Rheumatology (Oxford); 2014 May; 53(5):914-8. PubMed ID: 24441153
[TBL] [Abstract][Full Text] [Related]
3. Analysis of haematological changes in tofacitinib-treated patients with rheumatoid arthritis across phase 3 and long-term extension studies.
Schulze-Koops H; Strand V; Nduaka C; DeMasi R; Wallenstein G; Kwok K; Wang L
Rheumatology (Oxford); 2017 Jan; 56(1):46-57. PubMed ID: 28028154
[TBL] [Abstract][Full Text] [Related]
4. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of Latin American patients with rheumatoid arthritis: Pooled efficacy and safety analyses of Phase 3 and long-term extension studies.
Radominski SC; Cardiel MH; Citera G; Goecke A; Jaller JJ; Lomonte ABV; Miranda P; Velez P; Xibillé D; Kwok K; Rojo R; García EG
Reumatol Clin; 2017; 13(4):201-209. PubMed ID: 27317492
[TBL] [Abstract][Full Text] [Related]
5. Reversibility of peripheral blood leukocyte phenotypic and functional changes after exposure to and withdrawal from tofacitinib, a Janus kinase inhibitor, in healthy volunteers.
Weinhold KJ; Bukowski JF; Brennan TV; Noveck RJ; Staats JS; Lin L; Stempora L; Hammond C; Wouters A; Mojcik CF; Cheng J; Collinge M; Jesson MI; Hazra A; Biswas P; Lan S; Clark JD; Hodge JA
Clin Immunol; 2018 Jun; 191():10-20. PubMed ID: 29518577
[TBL] [Abstract][Full Text] [Related]
6. Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis.
Cohen S; Radominski SC; Gomez-Reino JJ; Wang L; Krishnaswami S; Wood SP; Soma K; Nduaka CI; Kwok K; Valdez H; Benda B; Riese R
Arthritis Rheumatol; 2014 Nov; 66(11):2924-37. PubMed ID: 25047021
[TBL] [Abstract][Full Text] [Related]
7. Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty-Four-Month, Phase III Study.
van der Heijde D; Strand V; Tanaka Y; Keystone E; Kremer J; Zerbini CAF; Cardiel MH; Cohen S; Nash P; Song YW; Tegzová D; Gruben D; Wallenstein G; Connell CA; Fleischmann R;
Arthritis Rheumatol; 2019 Jun; 71(6):878-891. PubMed ID: 30666826
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor.
Charles-Schoeman C; Wicker P; Gonzalez-Gay MA; Boy M; Zuckerman A; Soma K; Geier J; Kwok K; Riese R
Semin Arthritis Rheum; 2016 Dec; 46(3):261-271. PubMed ID: 27443588
[TBL] [Abstract][Full Text] [Related]
9. Risk Factors for Major Adverse Cardiovascular Events in Phase III and Long-Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis.
Charles-Schoeman C; DeMasi R; Valdez H; Soma K; Hwang LJ; Boy MG; Biswas P; McInnes IB
Arthritis Rheumatol; 2019 Sep; 71(9):1450-1459. PubMed ID: 31385441
[TBL] [Abstract][Full Text] [Related]
10. Comparative Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Receiving Tofacitinib Versus Those Receiving Tumor Necrosis Factor Inhibitors: An Observational Cohort Study.
Desai RJ; Pawar A; Weinblatt ME; Kim SC
Arthritis Rheumatol; 2019 Jun; 71(6):892-900. PubMed ID: 30552833
[TBL] [Abstract][Full Text] [Related]
11. Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme.
Curtis JR; Lee EB; Kaplan IV; Kwok K; Geier J; Benda B; Soma K; Wang L; Riese R
Ann Rheum Dis; 2016 May; 75(5):831-41. PubMed ID: 25902789
[TBL] [Abstract][Full Text] [Related]
12. Successful treatment of palmoplantar pustulosis with rheumatoid arthritis, with tofacitinib: Impact of this JAK inhibitor on T-cell differentiation.
Koga T; Sato T; Umeda M; Fukui S; Horai Y; Kawashiri SY; Iwamoto N; Ichinose K; Nakamura H; Kawakami A
Clin Immunol; 2016 Dec; 173():147-148. PubMed ID: 27720846
[No Abstract] [Full Text] [Related]
13. Relationship between lymphocyte count and risk of infection in Japanese rheumatoid arthritis patients treated with tofacitinib.
Tanaka Y; Takeuchi T; Valdez H; Collinge M; Zwillich SH; Toyoizumi S; Kwok K; Hirose T
Mod Rheumatol; 2024 Apr; ():. PubMed ID: 38801704
[TBL] [Abstract][Full Text] [Related]
14. Impact of tofacitinib treatment on human B-cells in vitro and in vivo.
Rizzi M; Lorenzetti R; Fischer K; Staniek J; Janowska I; Troilo A; Strohmeier V; Erlacher M; Kunze M; Bannert B; Kyburz D; Voll RE; Venhoff N; Thiel J
J Autoimmun; 2017 Feb; 77():55-66. PubMed ID: 27793425
[TBL] [Abstract][Full Text] [Related]
15. JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical.
Tanaka Y; Yamaoka K
Mod Rheumatol; 2013 May; 23(3):415-24. PubMed ID: 23212593
[TBL] [Abstract][Full Text] [Related]
16. Tofacitinib modulates the VZV-specific CD4+ T cell immune response in vitro in lymphocytes of patients with rheumatoid arthritis.
Almanzar G; Kienle F; Schmalzing M; Maas A; Tony HP; Prelog M
Rheumatology (Oxford); 2019 Nov; 58(11):2051-2060. PubMed ID: 31106368
[TBL] [Abstract][Full Text] [Related]
17. Tofacitinib: The First Janus Kinase (JAK) inhibitor for the treatment of rheumatoid arthritis.
Vyas D; O'Dell KM; Bandy JL; Boyce EG
Ann Pharmacother; 2013 Nov; 47(11):1524-31. PubMed ID: 24285764
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the efficacy and safety of tofacitinib and upadacitinib in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials.
Song GG; Choi SJ; Lee YH
Int J Rheum Dis; 2019 Aug; 22(8):1563-1571. PubMed ID: 31211506
[TBL] [Abstract][Full Text] [Related]
19. Tofacitinib: A Review in Rheumatoid Arthritis.
Dhillon S
Drugs; 2017 Dec; 77(18):1987-2001. PubMed ID: 29139090
[TBL] [Abstract][Full Text] [Related]
20. Systematic review of tofacitinib: a new drug for the management of rheumatoid arthritis.
Kaur K; Kalra S; Kaushal S
Clin Ther; 2014 Jul; 36(7):1074-86. PubMed ID: 25047498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
